Tag: Dr. Tansey

A new multinational, phase 3 clinical trial published online ahead of print in the European Journal of Endocrinology studied the growth promoting effects of once‑weekly growth hormone analog versus standard daily growth hormone (GH) therapy for children living with Noonan syndrome. The results show that the weekly analog approach is superior to the daily approach in terms of enhancing growth rate. The study, titled “Once‑weekly Somapacitan in Children with Noonan Syndrome: Randomised Controlled Phase 3 Trial”. The trial authors included contributions from Dr. Tansey from our Division. A total of 77 children with Noonan syndrome were enrolled in the trial and randomized 2:1 to the once‑weekly standard or daily GH preparations over a one-year period. The children receiving the weekly analog grew a little faster (13% on average, statistically significant) compared with the daily GH group. Importantly, the weekly analog was well tolerated, showing a safety profile comparable to daily GH. It will be important to ascertain the long term impact of the weekly analog on final adult height in this population. These findings highlight a promising, less burdensome therapeutic option for families. We thank Dr. Tansey for his role in advancing this impactful work. The abstract of the work can be found at this pubmed link.

Our division has contribution to a clinical study recently published in Diabetes Technology & Therapeutics : “Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study.” One of our Division physicians, Dr. Tansey, served as a co-author on this important research. This paper describes an extension phase to the INHALE-1 trial to better examine long-term safety of an inhaled form of insulin. The results from the first 26-week phase of trial were published several months ago. Inhaled insulin demonstrated similar glucose levels to conventional therapy with injected insulin but greater treatment satisfaction. The extension phase of the trial allowed participants the option to continue inhaled insulin for another 26 weeks to further evaluate safety. Even after one year’s treatment, there were no serious pulmonary complications among the participants. There was a small increase in hemoglobin A1c from week 26 to week 52 (from 8.2 to 8.6%). The manuscript abstract is available on Pubmed. The results show the potential safety of inhaled insulin for children with type 1 diabetes. We especially wish to thank the research coordinators, research participants and their families who made this study possible.

We are proud to announce our division’s contribution to a major clinical study recently published in Diabetes Care: “INHALE-1, A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes.” One of our Division physicians, Dr. Tansey, served as a co-author on this important research. The INHALE-1 trial examined the safety and effectiveness of an inhaled form of insulin compared to standard rapid-acting insulin injections in 230 children and adolescents aged 4 to 17 living with diabetes. Over a 26-week period, participants continued their long-acting basal insulin and used continuous glucose monitoring while receiving either inhaled or injected rapid acting insulin. Compared to the injected insulin group, the inhaled insulin group experienced a similar hemoglobin A1c, similar continuous glucose monitor readings, and lung function. Children using TI reported greater treatment satisfaction and experienced less weight gain compared to those on injected insulin. These findings suggest that inhaled insulin could become a valuable option for some pediatric patients. It is important to note that the study did not compare inhaled insulin to insulin pump-based therapy. The manuscript abstract is available on Pubmed. We especially wish to thank the research coordinators, research participants and their families who made this study possible.